FOLR1 and cancer: MORAb-202, an ADC that combines the humanized anti-human FRα antibody farletuzumab with the microtubule-targeting drug eribulin, has demonstrated substantial anticancer efficacy in cancer cell lines and in patient-derived xenograft models (63, 82).